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This 12-week study compared the efficacy and safety of a fixed combination of fluticasone pro-
pionate plus formoterol (FL/F) 250/12 mg b.i.d. administered via a dry powder inhaler (DPI)
(Libbs Farmaceˆutica, Brazil) to a combination of budesonide plus formoterol (BD/F) 400/
12 mg b.i.d. After a 2-week run-in period (in which all patients were treated exclusively with
budesonide plus formoterol), patients aged 12e65 years of age (N Z 196) with uncontrolled
asthma were randomized into an actively-controlled, open-labeled, parallel-group, multicen-
tre, phase III study. The primary objective was to demonstrate non-inferiority, measured by
morning peak expiratory flow (mPEF).
The non-inferiority was demonstrated. A statistically significant improvement from baseline
was observed in both groups in terms of lung function, asthma control, and the use of rescue
medication. FL/F demonstrated a statistical superiority to BD/F in terms of lung function
(FEV1) (p Z 0.01) and for asthma control (p Z 0.02). Non-significant between-group differ-
ences were observed with regards to exacerbation rates and adverse events.
In uncontrolled or partly controlled asthma patients, the use of a combination of fluticasone
propionate plus formoterol via DPI for 12-weeks was non-inferior and showed improvements in
FEV1 and asthma control when compared to a combination of budesonide plus formoterol.
(Clinical Trial number: ISRCTN60408425).
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Asthma is a worldwide disease associated with a growing
burden in terms of morbidity, lower quality of life, and
healthcare costs [1]. The goal of therapy in asthma is to
achieve and maintain clinical control by reducing the
patient’s exposure to factors that exacerbate asthma
and by using medications for the purposes of relief and
control. For patients with uncontrolled asthma treated with
inhaled corticosteroids (ICS) alone, international guidelines
recommend a combination of inhaled corticosteroids (ICS)
and long-acting b2-agonists (LABA) [1]. The use of an ICS/
LABA combination in 1 inhaler may be more effective due to
convenience and ease of use by improving patient compli-
ance and long-term control [2,3].
Fluticasone propionate is an inhaled corticosteroid with
high potency in vitro [4], high topical anti-inflammatory
activity [5], and a rapidly induced protective effect [6].
Fluticasone propionate has been shown to be effective in
adults and children with regards to treating chronic asthma
[7]. Formoterol is a LABA with a very quick onset of action
[8]. It has been used as a maintenance therapy and as a
relief medication in combination with an ICS [9].
The FL/F combination in a single, pressurized, metered
dose inhaler has been compared with the single agent
treatment of either propionate fluticasone or formoterol
and with combination of either fluticasone/salmeterol or
budesonide/formoterol which to the majority concluded
similar efficacy and safety [10e17]. In patients with severeasthma, the combination of FL/F showed similar efficacy
and similar patient tolerance [10] as compared to single
agents. In patients with mild-to-moderate asthma, the FL/F
combination showed superior efficacy compared to either
single agent fluticasone, formoterol, or placebo [13]. FL/F
in a single aerosol inhaler was also compared with flutica-
sone propionate plus salmeterol, resulting in similar effi-
cacy and a faster onset of action [11]. FL/F was also
compared with budesonide plus formoterol and, again,
showed comparable efficacy [12].
Chronic asthma control remains suboptimal despite
the continued development of improved treatments
for asthma, particularly in Latin America [18,19]. The
consequences of suboptimal asthma control include a
poor quality of life, frequent and urgent health care visits,
an increase in the risk of asthma exacerbations, and
increased mortality [20]. Alternative treatment options,
with different combinations and formulations, may provide
more flexibility with regards to adjusting to a patient’s
clinical severity and device preferences. This flexibility in
treatment has the potential to increase compliance and
effectiveness of therapy [21,22]. The rationale behind
combining fluticasone propionate and formoterol (FL/F) is
to provide the benefits of a high-potency anti-inflammatory
agent with the fast onset of action of a b-2 agonist in a new
formulation (dry powder) using a single inhaler.
Previous studies using metered dose inhaler showed
similar efficacy between FL/F and others combinations.
This is the first study to evaluate the fixed combination of
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in order to demonstrate the non-inferiority of the fixed
combination of FL/F in comparison with the fixed combi-
nation of budesonide/formoterol (BUD/F) in the treatment
of uncontrolled and partly controlled asthma patients. The
BUD/F combination was selected for comparison because it
contains the same LABA, i.e. formoterol.
Material and methods
Study design
This randomized, open, parallel-group study was conducted
over 12 weeks (with an additional 2-week run-in period) in
11 research centers in Brazil (Clinical Trial number:
ISRCTN60408425). The study was performed in accordance
with the Declaration of Helsinki and Good Clinical Practice,
and approved by an independent ethics committee on
human research at each institution. All patients were pro-
vided with written informed consent. The study was con-
ducted from August 2010 to March 2011.
The patients who qualified for the study based on the
inclusion and exclusion criteria (as described below) star-
ted a 2-week run-in period in which all patients were
treated with budesonide plus formoterol (Symbicort
Turbohaler) at a dose of 400/12 mg twice daily. At the
same time, they received PIKO-1 peak flow meters, rescue
medication (salbutamol), and diaries for data collection. All
other asthma medication was discontinued. Patients who
had satisfactory compliance (<8 missed doses during the
run-in period), had a predicted a post-bronchodilator FEV1
of >60%, and had uncontrolled or partially controlled
asthma, were randomized to receive the same dose of
budesonide plus formoterol used in the run-in period or
250 mg of fluticasone propionate plus 12 mg formoterol
twice daily (Duonare, Libbs Farmaceˆutica, Brazil). The
daily dose of 500 mg of propionate fluticasone used in this
study is equivalent of 800 mg of budesonide [1]. Lung
function assessments, reviews of patient’s diaries and
safety records were evaluated at weeks 4, 8 and 12. At each
visit, patients completed a lung function test before
receiving their morning dose.
Study patients
Males and females aged between 12 and 65 years, with a
diagnosis of asthma for 3 months prior to screening, a
body mass index between 19 and 30 kg/m2, and currently
receiving treatment with a combination therapy of a LABA
and an ICS (800 mg budesonide or equivalent) for 30 days
were included in the study. Patients were required to have
partially controlled (patients with at least one of the
following characteristic: daytime symptoms twice/week;
need for reliever treatment twice/week; any limitation of
activities; any nocturnal symptoms; or lung function less
than 80% of predicted value) or uncontrolled asthma [1] and
to have a post-bronchodilator FEV1 >60% of predicted value
in order to be eligible for randomization. Exclusion criteria
were defined as any of the following: current or ex-smokers
(>10 pack-years); pregnant or lactating; severe asthma
exacerbation during the run-in period; 3 or more courses oforal corticosteroids in the previous 6 months; hospitaliza-
tion due to asthma in the previous 6 months; any course of
oral corticosteroids 30 days prior to screening; concomitant
lung disease; treatment with anti-cholinergics, antihista-
mines, leukotriene receptor antagonists, beta blockers,
tricyclic antidepressant, methylxantines, ritonavir, or ke-
toconazole in the previous 2 weeks; or a morning cortisol
level lower than 5 mcg/dL.
Protocol outcome measures
The primary end point for the determination of efficacy of
study treatments was the mean change in morning PEF.
Patients used diaries in order to document morning and
evening PEF, document answers to questions of the
Asthma Control Questionnaire (ACQ-7 validated in Brazil
and allowed for use in this study) [23,24], and to keep re-
cord of salbutamol and other medication use. Diaries
were collected at each study visit. Patients performed a
measured morning and evening PEF by using a portable
PIKO-1 peak flow meter (nSpire Health Inc). All measure-
ments were documented in diaries and the highest of the 3
results was automatically recorded in a calendar. The pa-
tients underwent spirometry (in accordance with the Bra-
zilian Thoracic Society [25]) at screening and at each of the
study visits. Reference ranges were calculated based on
statistics formulated from the Brazilian population [26,27].
Patients recorded their use of rescue medication as the
number of puffs of salbutamol taken in each 24-h period. At
week 12, investigators rated each patient’s response to
therapy compared with their baseline in a 5-point scale
from 1 (much improved) to 5 (much worse). Medication use
was measured by the assessment of used blister packs (for
FL/F) and by a dose counter (for BD/F).
Daily data collection included the morning and evening
PEF and asthma control days. For PEF analysis, however, it
was used the average of 2 weeks run in period and 2 weeks
period before follow-up visits. To the asthma control
analysis, it was also measured the average of the Asthma
Control Questionnaire score during the 2-week baseline and
at 2 weeks before follow-up visits.
Safety assessments
Adverse events were reported throughout the study period.
A physical examination (including an oropharyngeal exam-
ination and vital signs measurements) was performed at the
pre-randomization visit and at each subsequent visit (day 1,
weeks 4, 8, and 12). Clinical laboratorial tests (complete
blood count, serum glucose, serum potassium, plasma
cortisol, and a 24-h urinary free cortisol) and a 12elead ECG
were performed at baseline and at the end of the study.
Statistics
A sample size of 180 patients and a standard deviation (SD)
of 45 L/min were required in order to provide a power of
80% with respect to non-inferiority. Non-inferiority was
concluded if the lower limit of the 97.5% confidence in-
terval (CI) for the treatment difference (fluticasone/for-
moterol e budesonide/formoterol) was 20 L/min.
Table 1 Baseline characteristics of the 196 patients.
FL/F BD/F p Value
Female sex e
no. (%)
74 (76.3) 72 (72.7) 0.56
Age e years 34.5  15.0 35.6  17.6 0.65
Caucasian
race e no. (%)
65 (67.0) 71 (71.7) 0.33
Duration of
asthma e years
22.8  13.2 21.4  13.4 0.40
Weight e kg 68.2  14.8 65.9  15.2 0.28
Ex-smoker e
no. (%)
14 (14.4) 10 (10.1) 0.35
Morning PEF e
L/min
355.6  115.5 345.1  124.2 0.54
Evening PEF e
L/min
362.5  121 351.4  123.5 0.53
FEV1 e L 2.51  0.71 2.50  0.77 0.95
FEV1% e %
predicted
85.5  18.6 85.2  17.6 0.90
ACQ-7 scorea 0.93  0.69 0.87  0.64 0.52
FL/F: Fluticasone propionate/formoterol group; BD/F: Bude-
sonide/formoterol group; PEF: Peak expiratory flow; FEV1:
forced expiratory volume in 1 s; ACQ: Asthma Control Ques-
tionnaire.
Data expressed as mean  SD.
a Scores on the Asthma Control Questionnaire range from 0 to
6, with a higher score indicating worse asthma control; the
minimal important difference (MID) is 0.5.
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(ITT) population, defined as patients who had taken at least
1 dose of the study medication and provided some post-
baseline efficacy data. A per-protocol population (PP)
analysis was also included e reported. The reasons for early
discontinuation included lack of compliance, patient
request, adverse effects, or pre-defined reasons for
discontinuation.
The Student’s t test was used for comparing baseline
variables between the groups, absolute means related to
lung function, asthma control scores, and measurements of
rescue medication. The number of patients with asthma
exacerbations was analyzed using Chi-square test. Changes
in lung function from baseline were measured via analysis
of covariance with the fixed effect of treatment and the
baseline as a covariate. Changes in laboratory analysis from
baseline were compared using the Student’s t test (para-
metric) or ManneWhitney test (non-parametric) according
to the statistical distribution.
Descriptive statistics included: counts and percentages
for categorical variables; means and standard deviations
for normally distribution variables; and medians, including
variables defined by first and third quartiles, that were not
normally distributed on the original or log-transformed
scales (SAS statistical-analysis software, version 9.1.3,
was used for these analyses).
Results
Overall, 274 patients were enrolled and 196 patients were
randomized and entered the treatment period (97 patients
were randomly assigned to the FL/F arm and 99 to the BD/F
arm). Patient flow and baseline characteristics are shown
in Fig. 1 and Table 1. In the fluticasone/formoterol
and budesonide/formoterol groups, 84 and 85 patientsFigure 1 Flow of patients. BD/F: budesonide/formcompleted the study and were included in the per-protocol
(PP) analysis, respectively. The treatment groups of the ITT
population were comparable in terms of their demograph-
ical and baseline characteristics (Table 1).oterol; FL/F: Fluticasone propionate/formoterol.
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female (74.5%). The average age was 35.1 years, with 19.9%
adolescents aged between 12 and 18 years. The mean
baseline FEV1 before bronchodilation was 2.50  0.74 L
(85.3  18% of the predicted value). There were no dif-
ferences in terms of demographical and baseline charac-
teristics in the treatment groups of the PP population.
Patient compliance was greater in the FL/F group than
the BD/F group (mean percentage of administered drug
93.8  9.9% in FL/F versus 87.2  12.9 in BD/F).
Primary outcome
For both treatment groups, average morning PEF was
automatically recorded by peak flow meter and increased
significantly by week 12 (both p < 0.05) (Fig. 2). Non-
inferiority was achieved in the ITT and PP analysis with
respect to morning PEF as the lower limit of the CI for the
treatment differences (12.6 L/min in the ITT population)
was > of 20 L/min for the morning PEF, as recorded using
peak flow meter. There was no significant difference in the
change from baseline between treatment groups (Table 2)
(Fig. 3).
Secondary outcomes
The mean FEV1 values for the FL/F group at baseline, week
4, week 8, and week 12 were 2.52 L, 2.66 L, 2.71 L, and
2.67 L, respectively. For the BD/F group the mean FEV1
values at baseline, week 4, week 8, and week 12 were
2.51 L, 2.50 L, 2.49 L, and 2.53 L, respectively. An increase
from the baseline FEV1 was observed in the FL/F treatment
group at weeks 4, 8, and 12 and were statisticallyFigure 2 Change over time of the morning PEF in the intention to
formoterol; **p < 0.05 versus baseline using last observation carriesignificant (all with p < 0.01). There was no statistically
significant change from the baseline during any period of
evaluation in the BD/F group. In addition, the increase in
the mean FEV1 from baseline to week 12 was significantly
greater in patients receiving FL/F than in patients receiving
BUD/F (Table 2). The time course of change in FEV1 for the
PP population is shown at Fig. 2.
We observed in both groups a statistically significant
improvement in the ACQ7 score from baseline (mean values
at baseline and at the end of the study were 0.93 to 0.64 in
the FL/F group, respectively; and 0.87 to 0.73 in the BD/F
group, respectively; p < 0.01 for both groups). In the FL/F
group, A statistically significant difference was observed in
the ACQ7 score from baseline to week 12 (pZ 0.02) (Table
2). With regards to rescue salbutamol use, the FL/F group
showed less use over the time of the study (mean values at
baseline and at the end of the study were, 1.1 and
0.57 puffs/day, respectively; p < 0.01). The BD/F group
failed to show a statistically significant reduction in rescue
salbutamol use (mean values at baseline and at the end of
the study were 0.71 and 0.60 puffs/day, respectively;
p Z 0.058). There were no statistically significant differ-
ences from baseline to the end of the study in terms of the
evening PEF.
In the ITT population, there were no statistically sig-
nificant differences between treatment groups when
considering either the change in the evening PEF or the use
of rescue salbutamol from baseline to week 12 (p Z 0.19,
p Z 0.29; respectively) (Table 2).
For all secondary outcomes, PP analysis showed similar
results.
At week 12, 78.6% of the patients in the FL/F group
and 69.4% of the patients in the BD/F group were rated
by investigators as “improved” or “much improved”; thistreat population.-: Fluticasone/formoterol;:: Budesonide/
d forward procedure.
Figure 3 Change over time in FEV1 in the intention to treat population.-: Fluticasone/formoterol;:: Budesonide/formoterol;
**p < 0.05 versus baseline using last observation carried forward (LOCF) procedure; #p < 0.05 between treatments using LOCF
procedure.
Table 2 Outcome variables in the intention-to-treat population (mean change from baseline).
FL/F BD/F p Value
Morning PEF e L/min
Baseline (Mean  SD) 355.6 (115.5) 345.1 (124.2)
End of Study (Mean  SD) 379.9 (137.3) 356.6 (134.4)
Change from baseline (Mean  SD) 24.3 (85.9) 11.5 (92.6) 0.32
Evening PEF e L/min
Baseline (Mean  SD) 362.5 (121.0) 351.4 (123.5)
End of Study (Mean  SD) 380.5 (129.7) 355.3 (131.0)
Change from baseline (Mean  SD) 18.0 (78.1) 3.9 (73.9) 0.19
Prebroncodilatador FEV1 e L
Baseline (Mean  SD) 2.52 (0.71) 2.51 (0.77)
End of Study (Mean  SD) 2.66 (0.74) 2.52 (0.73)
Change from baseline (Mean  SD) 0.14 (0.41) 0.01 (0.27) 0.01
FEV1 e percent of predicted value before bronchodilation
Baseline (Mean  SD) 85.8 (18.8) 85.3 (17.4)
End of Study (Mean  SD) 91.2 (19.4) 86.2 (16.6)
Change from baseline (Mean  SD) 5.4 (11.1) 0.9 (10.5) <0.01
Salbutamol rescue use e puffs/day
Baseline (Mean  SD) 1.10 (2.57) 0.71 (1.09)
End of Study (Mean  SD) 0.57 (1.25) 0.61 (1.17)
Change from baseline (Mean  SD) 0.53 (2.46) 0.08 (0.75) 0.29
ACQ7 score
Baseline (Mean  SD) 0.93 (0.69) 0.87 (0.64)
End of study (Mean  SD) 0.64 (0.63) 0.73 (0.65)
Change from baseline (Mean  SD) 0.30 (0.48) 0.14 (0.47) 0.02
Data are presented as mean  SD. FL/F: Fluticasone propionate/formoterol group; BD/F: Budesonide/formoterol group; PEF: peak
expiratory flow; FEV1: forced expiratory volume in 1 s; ACQ: Asthma Control Questionnaire.
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icant (p Z 0.29).
Tolerability
During the study, 193 non-serious adverse events were re-
ported: 93 among patients receiving fluticasone/formoterol
and 100 among patients receiving budesonide/formoterol.
The most commonly reported adverse events are listed in
Table 3. Oral candidiasis was infrequent, occurring only in 1
patient receiving budesonide/formoterol. A total of 5
serious adverse events occurred: 2 among patients
receiving fluticasone/formoterol (1 patient who underwent
elective, gynecologic surgery and 1 patient who experi-
enced a post-procedural headache) and 3 among patients
receiving budesonide/formoterol (1 patient who developed
pneumonia, 1 patient who developed facial nerve palsy,
and 1 patient who was found to have a gallstone). Six pa-
tients in each group experienced a severe asthma exacer-
bation requiring an oral corticosteroid and 1 patient in each
treatment group discontinued the study because of adverse
events.
Laboratory evaluations showed no statistically signifi-
cant differences between the treatment groups. A small
increase in aspartate aminotransferase and in alanine
aminotransferase (mean 7.7 U/L and 3.8 U/L, respectively)
was observed in the FL/F group; however, this was not
considered to be clinically significant. There were no dif-
ferences between treatment groups in terms of the change
from baseline with regards to the 8:00AM serum cortisol
concentration (p Z 0.10) or the 24-h urinary free cortisol
(p Z 0.36). Blood pressure and heart rate were stable
throughout the study period in both treatment groups with
no clinically relevant changes.
Discussion
This is the first study to evaluate and compare the combi-
nation of fluticasone propionate plus formoterol adminis-
tered via a dry powder inhaler to budesonide plus
formoterol in uncontrolled asthma patients. The results of
the study show the non-inferiority of fluticasone propionate
plus formoterol to budesonide plus formoterol during 12-
weeks on the basis of the predefined criteria of morning
PEF. Morning PEF, rescue medication use, and asthma
control improved in relation to the baseline in bothTable 3 Adverse events occurring in >2% of patients in
either treatment group in the intention-to-treat population.
Adverse event FL/F BD/F
Influenza-like symptoms 8 (8.2) 13 (13.2)
Asthma exacerbation 10 (10.3) 12 (12.1)
Headache 11 (11.3) 4 (4)
Upper respiratory tract infection 8 (8.2) 4 (4.0)
Sinusitis 4 (4.1) 3 (3.0)
Cough 1 (1.0) 3 (3.0)
Data are presented as number (%). FL/F: Fluticasone propio-
nate/formoterol group; BD/F: Budesonide/formoterol group.treatment groups. A greater improvement in FEV1 and
asthma control was also seen in uncontrolled and partly
controlled asthma patients who used FL/F compared to
those who used BD/F, with no difference considering need
to rescue therapy and PEF measures.
Theobserved improvement in thepre-bronchodilator FEV1
and asthma control with the fixed combination FL/F may be
related to the efficacy of the fluticasone propionate compo-
nent. Experimental studies have shown that fluticasone
propionate shows a higher affinity for the human glucocorti-
coid receptor [28] than does budesonide and has superior
trans-repress AP-1 or NF-kB activity [4]. Clinical experience
has also shown an increase in lung function after treatment
with fluticasone propionate relative to budesonide, as
demonstrated by improvements in morning PEF observed in
a meta-analysis involving 7 comparative trials [29].
The difference in efficacy observed may be also related
to the type of inhaler. Both medications were adminis-
trated via a dry powder inhaler. However, therapy
compliance [30] and delivery of the drug to the lungs [31]
may change with the use of different DPI, and FL/F was
administrated using an inhaler with improvements to
reduce patients with difficult to handle the inhaler (easier
to open the lid and to pierce the capsule, more friendly
designed) [32]. In our study, we observed better compli-
ance with the FL/F inhaler which may have contributed to
the better results of combining fluticasone and formoterol.
The clinical relevance of these statistical differences is
difficult to estimate. Pre-bronchodilator FEV1 is a strong,
independent predictor of the risk of asthma exacerbations
[29]. However, based on studies of the subjective percep-
tion by patients, the minimal increase required in FEV1 for a
patient to notice improvement is about 0.23 L (or 10%)
[33,34]. Based on this data, the difference observed in our
study may not be clinically significant. Likewise, a change
of 0.5 in the ACQ has been reported as the cut off for
clinical improvement [34]. Therefore, the difference in the
ACQ observed in our study may not be clinically significant,
either.
During the 3-month study period, the FL/F combination
was tolerated just as well as the BUD/F combination. The
most common adverse effects in each group (influenza-like
symptoms and asthma exacerbations) can probably be
attributed to seasonal factors, as suggested by their similar
frequency in the 2 groups. There was no evidence of
detrimental effects on the cardiovascular system (no
changes in ECG tracings) or the adrenal axis (based on
morning cortisol levels and 24-h urinary free cortisol levels).
A limitation of the present study is the open label
design. However, the results are unlikely to be influenced
by investigator bias, by design, or by converting all patients
to BUD/F during run-in. It could be argued that these may
have encouraged patients to be more motivated in FL/F
arm, leading to an inbuilt bias influencing patient’s
behavior and adherence. However, a number of precautions
were taken to minimize bias. First, expectation bias was
minimized by training all patients to use correctly the
inhalation device and by stressing the relevance of the
correct use of treatment and compliance at each visit.
Second, to reduce expectation bias of patients and in-
vestigators [35] we chose as primary outcome an objective
measure. It is impossible to determine whether how
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results because it may affect adherence in two opposite
ways: increasing adherence due to motivation/hope or
reducing adherence due to the individual preferences [36].
Finally, we also performed a PP analysis without non-
adherent patients and the results were the same.
As a consequence of our study design, we cannot
comment on either the rate of asthma exacerbation or
long-term safety issues. Longer longitudinal studies, with
sufficient statistical power, will be needed in order to
evaluate exacerbations and additional safety events.
In conclusion, this study showed the non-inferiority of
the combination of FL/F to BD/F in asthmatics not
controlled with other ICS/LABA combinations. The data also
suggests an improvement in terms of lung function and
asthma control after 12-weeks of treatment in patients
using the combination FL/F. The findings of this study
support the use of fluticasone propionate plus formoterol
(as a dry powder combination) as an option in treating
uncontrolled asthma patients. Many asthmatic patients still
show poor control despite of the use of combination ther-
apy. As an alternative for asthma treatment, this formula-
tion may offer a new option in asthma medication and
delivery when considering patient preference and treat-
ment response. Further double blind studies powered to
evaluated superiority are required to establish differences
between therapies.References
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